# MARKET_RESEARCH_LOG_2026-08-26

> Production V3.1 hourly scan handoff. Repository `main` remains the source of truth. This log records the latest completed production artifacts available to each run and must not be interpreted as an automatic trading instruction.

## 2026-08-26 01:10 CST — hourly production scan

### Canonical rules / data provenance

- Repository rules read from latest `main`: `AGENTS.md`, `CURRENT_MARKET_RESEARCH.md`, `RESEARCH_QUEUE.md`, `MODEL_EVOLUTION_LOG.md`, and current V3.1 production workflow/configuration.
- Production workflow status: latest `V3.1 Every-Industry Research` run inspected by this scan completed successfully (`run_id=32873471270`, run #51); latest Postscan research artifact in the same production cycle also completed and was inspected (`run_id=32873471268`).
- Latest verified A-share trade date in the valuation/quant artifacts: `2026-08-25`.
- Price freshness: `FRESH` for the latest completed production artifact where `latest_trade_date/qfq_latest_trade_date/raw_latest_trade_date=2026-08-25`; stale/unverified prices remain prohibited from producing Formal BUY.
- Execution-universe policy: only execution-eligible Shanghai/Shenzhen A shares may become actual buy candidates. Research-only codes remain excluded from Formal BUY.

### Production funnel

- Industry coverage: 83 industries, 383 industry candidates; 82 industries had a clean candidate.
- Frozen V3.1 deep-review queue: 375 names.
- Execution-universe eligible within the review queue: 294; research-only: 81.
- `v31_candidate_class`: all 375 are `PENDING`.
- `v31_a_eligible=true`: **0**.
- `v31_buy_ready=true`: **0**.
- Long-term second-pass candidates: 3 (`603658 安图生物`, `688526 科前生物`, `688687 凯因科技`), but all remain blocked from long-term Formal BUY under the frozen V3.1 contract.
- Postscan master research ranking: 399 names; `actionable_long_term_count=0`.
- Long-term Formal BUY: **0**; BUY-ready: **0**; TRY-position: **0**.
- No automatic promotion and no automatic trading are permitted by the inspected artifacts.

### A1 / A2 / WATCH / WAIT / INVALIDATED

- **A1:** 0 new executable names.
- **A2:** 0 new executable names.
- **WATCH:** research queue remains broad; no WATCH name was promoted into A1/A2 in this run.
- **WAIT:** all production names that look technically/valuation-interesting but lack completed evidence-backed V3.1 hard gates remain WAIT / research-required rather than BUY.
- **INVALIDATED:** no new thesis invalidation or forced-exit event was identified by the inspected production artifacts.

### Nearest-looking blocked names are not Formal BUY

`603658 安图生物` is execution-universe eligible and the postscan layer shows an entry-condition-present review state around a verified current price of 34.17 with an indicated entry band 33.58–34.15. It is **not** Formal BUY because the frozen V3.1 evidence layer still has unresolved/unknown hard gates (predictability, long-term demand, moat, financial safety, earnings authenticity), A-class is not proven, scenario valuation / expectation-gap / downside / falsification work is incomplete, and `v31_buy_ready=false`.

`688526 科前生物` and `688687 凯因科技` are additionally `RESEARCH_ONLY` for execution-universe purposes and therefore cannot become actual buy candidates for this user even before the remaining V3.1 evidence blockers are resolved.

### Valuation / buy-band changes

- No A1/A2 valuation range or executable buy range was created or materially changed in this run.
- Any pre-existing manual/working valuation examples in `CURRENT_MARKET_RESEARCH.md` remain prior research context only; they are not promoted by this production scan.
- No threshold was relaxed to manufacture a BUY.

### Rejections / blockers

The dominant reason no Formal BUY exists is not merely price. The frozen V3.1 review queue remains fail-closed when required qualitative and valuation evidence is incomplete. Typical blockers include:

- hard-gate evidence unknown/incomplete for predictability, long-term demand, moat, financial safety, or earnings authenticity;
- A-class not proven / V3.1 score incomplete;
- normalized profit / Bear-Base-Bull scenario valuation incomplete;
- implied expectation / expectation gap incomplete;
- risk-adjusted 3Y CAGR / downside / falsification incomplete;
- clear margin-of-safety and other Formal BUY conditions not proven;
- execution-universe blocked for research-only names.

### Delta versus prior handoff / latest production state

- Freshness improved versus the old durable handoff that warned exact current prices were unverified: the latest production artifact is explicitly dated to the 2026-08-25 trade date.
- This freshness improvement did **not** create an executable opportunity: A-eligible remains 0 and Formal BUY remains 0.
- No new A1/A2 promotion, no material buy-band change, no hard-logic invalidation, and no production/CI failure were found in this run.

### Confidence / reproducibility

- Scan-result confidence: **HIGH** for the statement that there is currently no production-grade Formal BUY in the inspected latest completed artifacts.
- Candidate-level fundamental/valuation confidence remains intentionally lower where frozen V3.1 evidence is incomplete; those names stay PENDING/WAIT.
- Reproduction anchors: production run `32873471270`, postscan run `32873471268`, latest trade date `2026-08-25`, policy `selection_framework_v3_1_frozen` / `long_term_formal_buy_v2_v31_frozen`.

### Formal BUY

**Formal BUY = NONE.**

---

## 2026-08-26 03:06 CST — hourly production scan

### Canonical rules / data provenance

- Re-read latest `main` durable rules and handoffs before interpreting artifacts: `AGENTS.md`, `CURRENT_MARKET_RESEARCH.md`, `RESEARCH_QUEUE.md`, `MODEL_EVOLUTION_LOG.md`, `V31_CANDIDATE_LEDGER.md`, and this daily log.
- Latest completed `GenGe V3.1 Every-Industry Research`: **success**, `run_id=32885281412`, run #72, created 2026-08-26 02:42 CST and completed about 02:44 CST.
- Latest completed `GenGe Postscan Research Pipeline`: **success**, `run_id=32885281466`, run #500, completed about 02:45 CST.
- Latest verified A-share trade date remains `2026-08-25`; for `603658`, raw/qfq/latest trade date all equal 2026-08-25 and verified current price is 34.17.
- Price freshness: **FRESH** for the inspected production artifact. No stale-price override was used.
- Execution universe: actual candidates restricted to eligible SSE/SZSE ordinary A shares; `688526` and `688687` remain research-only for this user's execution scope.

### Production funnel

- Industry coverage: **83 industries / 383 industry candidates / 83 clean industries**.
- Frozen V3.1 deep-review queue expanded to **500 names**, all `RESEARCH_REQUIRED`; automatic gate inference remains forbidden.
- Long-term second pass remains exactly 3 names: `688526 科前生物`, `603658 安图生物`, `688687 凯因科技`.
- Postscan master ranking: **456 names**; `actionable_long_term_count=0`, `buy_ready_count=0`, `try_position_count=0`, `blocked_long_term_count=3`.
- Long-term Formal BUY: **0**; BUY-ready: **0**; TRY-position: **0**.
- Zero-buy audit examined 4525 candidates and again required second pass; it did not authorize bypassing hard safety gates.

### Candidate state / ledger delta

- **A1:** 0 new executable names.
- **A2:** 0 new executable names.
- **WATCH:** no new execution-eligible name entered the durable deep-research queue.
- **WAIT / RESEEN:** `603658 安图生物` reproduced as the only current execution-eligible durable deep-research candidate. Verified price **34.17**, observed entry band **33.58–34.15**, risk invalidation reference **33.07**, targets 36.80 / 37.51, real reward/risk 2.45. These execution-plan fields do **not** constitute Formal BUY because the frozen V3.1 hard gates and scenario valuation remain incomplete.
- **INVALIDATED:** none.
- **Ledger delta:** `RESEEN 603658`; no `NEW`, `UPGRADED`, `DOWNGRADED`, `INVALIDATED`, or material `PRICE_ONLY_CHANGE`.

### Why 603658 is still blocked

The latest frozen V3.1 row still has:

- `v31_candidate_class=PENDING`
- `v31_hard_gates_passed=false`
- unknown hard gates: predictability, long-term demand, moat, financial safety, earnings authenticity
- `v31_a_eligible=false`
- `v31_buy_ready=false`
- scenario valuation / implied expectation / expectation gap / risk-adjusted CAGR / downside / falsification incomplete
- Formal signal eligibility=false and no automatic promotion.

Production financial diagnostics report `financial_review_status=OK`, `earnings_quality_score=57`, `earnings_quality_confidence=HIGH`, and normalized source profit from reported recurring profit, but those diagnostics do not replace the missing company-level V3.1 qualitative hard-gate evidence.

### Delta versus 01:10 CST handoff

- Production and Postscan remain healthy; no CI/data-source failure was detected.
- Industry clean coverage improved from 82 to 83 industries; deep-review breadth expanded from 375 to 500 names and postscan master breadth from 399 to 456.
- These breadth changes did **not** produce a new A1/A2, actionable long-term name, Formal BUY, valuation-band change, or thesis invalidation.
- `603658` price and entry band are unchanged, so this is a **RESEEN**, not a new opportunity alert.

### Confidence / reproducibility

- Confidence: **HIGH** that the inspected latest production state contains no production-grade Formal BUY.
- Reproduction anchors: `run_id=32885281412`, Postscan `run_id=32885281466`, artifact ids `9577398597` / `9577455502`, latest trade date `2026-08-25`, frozen policies `selection_framework_v3_1_frozen` and `long_term_formal_buy_v2_v31_frozen`.

### Formal BUY

**Formal BUY = NONE.**

---

## 2026-08-26 06:09 CST — hourly production scan

### Canonical rules / data provenance

- Re-read the latest `main` rule/evidence chain before interpreting this round: `AGENTS.md`, `CURRENT_MARKET_RESEARCH.md`, `RESEARCH_QUEUE.md`, `MODEL_EVOLUTION_LOG.md`, `V31_CANDIDATE_LEDGER.md`, this daily log and `V31_DURABLE_HANDOFF.md`.
- Latest completed `GenGe V3.1 Every-Industry Research`: **success**, `run_id=32902392600`.
- Latest completed `GenGe Postscan Research Pipeline`: **success**, `run_id=32902392565`; its upstream full-A production artifact came from `run_id=32900338757`.
- Postscan focused regression suite: **130 passed, 1 warning**.
- Latest verified A-share trade date remains **2026-08-25**. At this pre-open scan there is no newer trading-day price; `603658` remains verified at **34.17 CNY** on 2026-08-25. No stale-price override is permitted.
- Execution universe remains restricted to execution-eligible Shanghai/Shenzhen ordinary A shares; `688526` and `688687` stay research-only for this user's actual execution scope.

### Production funnel

- Industry map: **383 candidates / 83 clean industries**.
- Valuation research: **320 names**.
- Long-term second pass: exactly **3 names** — `688526 科前生物`, `603658 安图生物`, `688687 凯因科技`.
- Master opportunity ranking: **456 names**.
- `actionable_long_term_count=0`, `buy_ready_count=0`, `try_position_count=0`, `blocked_long_term_count=3`.
- Long-term Formal BUY count: **0**.
- Zero-buy audit examined **4525** candidates, found market regime `GREEN`, and still required a second pass rather than allowing hard-gate bypass.
- Specialized valuation stayed fail-closed/no-auto-trade; no sidecar valuation was permitted to auto-promote a candidate.

### Candidate state / ledger delta

- **A1:** no new execution-eligible A1.
- **A2:** no new execution-eligible A2.
- **WATCH:** no new execution-eligible name entered the durable deep-research queue.
- **WAIT / RESEEN:** `603658 安图生物` remains the only durable execution-eligible deep-research candidate. Tier **WAIT**, Formal BUY **NO**, verified close **34.17**, observed entry band **33.58–34.15**.
- **INVALIDATED:** none.
- **Ledger delta:** `RESEEN 603658` only. No `NEW`, `UPGRADED`, `DOWNGRADED`, `INVALIDATED`, or material `PRICE_ONLY_CHANGE`.

### Fundamental / valuation status

The negative 2026H1 evidence recorded at 05:06 CST remains the controlling company-level update: revenue was approximately flat, attributable profit fell 12.94% YoY and operating cash flow fell 47.38% YoY. That evidence continues to strengthen the blockers rather than justify promotion. The formal moat/predictability/financial-safety audit, normalized sustainable earnings, Bear/Base/Bull reverse valuation, implied expectation/required growth, expectation gap, downside and falsification work remain incomplete.

The observed execution band is therefore only a research/entry-condition reference. It cannot override the missing V3.1 hard gates and does not authorize a Formal BUY.

### Delta versus 05:06 CST durable handoff

- No new eligible deep-research candidate.
- No A1/A2 promotion.
- No valuation range or executable buy-band change.
- No Formal BUY.
- No thesis invalidation/exit event.
- Production chain, artifact download, focused tests and postscan pipeline all completed successfully; no CI/data-source failure was identified.

### Confidence / reproducibility

- Confidence: **HIGH** that this latest completed production cycle contains no production-grade Formal BUY.
- Reproduction anchors: Every-Industry `run_id=32902392600`, Postscan `run_id=32902392565`, upstream full-A `run_id=32900338757`, latest verified trade date `2026-08-25`, frozen policy `long_term_formal_buy_v2_v31_frozen`.

### Formal BUY

**Formal BUY = NONE.**
